Varsha Gandhi, PhD, on Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opening Session Panel Discussion

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Oct

Today In Oncology

Varsha Gandhi, PhD, on Ibrutinib

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opening Session Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations

In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival

Kidney Cancer Cases Expected to Double by 2050

CT-Adapative SBRT for Recurrent Retroperitoneal Sarcomas

Variation in PSA Levels in Annual Testing Among Individuals Without Prostate Cancer Diagnosis